{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:31:16Z","timestamp":1793399476822,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260555"],"award-info":[{"award-number":["82260555"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Innovation and Development Project of Lanzhou University","award":["lzuyxcx-2022-177"],"award-info":[{"award-number":["lzuyxcx-2022-177"]}],"id":[{"id":"https:\/\/ror.org\/01mkqqe32","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018554","name":"Science and Technology Program of Gansu Province","doi-asserted-by":"publisher","award":["22ZD6FA021-4"],"award-info":[{"award-number":["22ZD6FA021-4"]}],"id":[{"id":"10.13039\/501100018554","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joint Research Fund General Projects of Gansu Province","award":["23JRRA1508"],"award-info":[{"award-number":["23JRRA1508"]}]},{"name":"Gansu Provincial Top-notch Talent Program","award":["(2023)9"],"award-info":[{"award-number":["(2023)9"]}]},{"name":"Public Hospital High-quality Development of Scientific Research Project of Chinese Health Promotion Foundation","award":["GL-C032"],"award-info":[{"award-number":["GL-C032"]}]},{"DOI":"10.13039\/501100009620","name":"Science and Technology Department of Gansu Province","doi-asserted-by":"publisher","award":["24JRRA469"],"award-info":[{"award-number":["24JRRA469"]}],"id":[{"id":"10.13039\/501100009620","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-026-02991-4","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:47:39Z","timestamp":1787726859000},"page":"3433-3450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global landscape of clinical trials and therapeutic targets in metabolic dysfunction-associated steatotic liver disease: an integrative multi-omics analysis"],"prefix":"10.1007","volume":"49","author":[{"given":"Yanxi","family":"Mu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixiong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haofei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wence","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"1","key":"2991_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK et al (2020) A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement [J]. J Hepatol 73(1):202\u2013209","journal-title":"J Hepatol"},{"key":"2991_CR2","doi-asserted-by":"crossref","unstructured":"Eslam M, Sanyal AJ, George J, Mafld (2020) A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease [J]. Gastroenterology 158(7):1999\u20132014","DOI":"10.1053\/j.gastro.2019.11.312"},{"issue":"3","key":"2991_CR3","first-page":"912","volume":"160","author":"ZM Younossi","year":"2020","unstructured":"Younossi ZM, Corey KE, Lim JK (2020) AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease. Expert Rev [J] Gastroenterol 160(3):912\u2013918","journal-title":"Expert Rev [J] Gastroenterol"},{"issue":"1","key":"2991_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","volume":"7","author":"X Xu","year":"2022","unstructured":"Xu X, Poulsen KL, Wu L et al (2022) Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH) [J]. Signal Transduct Target Therapy 7(1):287","journal-title":"Signal Transduct Target Therapy"},{"issue":"6","key":"2991_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S2468-1253(26)00011-7","volume":"11","author":"Global burden of","year":"2026","unstructured":"Global burden of (2026) metabolic dysfunction-associated steatotic liver disease, 1990\u20132023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023 [J]. Lancet Gastroenterol Hepatol 11(6):463\u2013494","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"2991_CR6","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature [J]. Hepatology 78(6):1966\u20131986","journal-title":"Hepatology"},{"issue":"3","key":"2991_CR7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"EASL-EASD-EASO Clinical","year":"2024","unstructured":"EASL-EASD-EASO Clinical (2024) Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) [J]. J Hepatol 81(3):492\u2013542","journal-title":"J Hepatol"},{"issue":"7","key":"2991_CR8","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M et al (2018) Mechanisms of NAFLD development and therapeutic strategies [J]. Nat Med 24(7):908\u2013922","journal-title":"Nat Med"},{"key":"2991_CR9","doi-asserted-by":"crossref","unstructured":"Stefan N, Yki-J\u00e4rvinen H, Neuschwander-Tetri BA (2025) Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment [J]. The Lancet Diabetes & Endocrinology 13(2):134\u2013148","DOI":"10.1016\/S2213-8587(24)00318-8"},{"key":"2991_CR10","doi-asserted-by":"crossref","unstructured":"Huang DQ, Noureddin N, Ajmera V et al (2023) Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis [J], vol 8. The lancet Gastroenterology & hepatology 8(9):829\u2013836","DOI":"10.1016\/S2468-1253(23)00157-7"},{"issue":"1","key":"2991_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","volume":"27","author":"VT Samuel","year":"2017","unstructured":"Samuel VT, Shulman GI (2017) Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases [J]. Cell Metab 27(1):22\u201341","journal-title":"Cell Metab"},{"issue":"2","key":"2991_CR12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jhep.2025.02.033","volume":"83","author":"GR Steinberg","year":"2025","unstructured":"Steinberg GR, Valvano CM, De Nardo W et al (2025) Integrative metabolism in MASLD and MASH: Pathophysiology and emerging mechanisms [J]. J Hepatol 83(2):584\u2013595","journal-title":"J Hepatol"},{"issue":"3","key":"2991_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","volume":"16","author":"K Kazankov","year":"2019","unstructured":"Kazankov K, J\u00f8rgensen SMD, Thomsen KL et al (2019) The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [J]. Nat Rev Gastroenterol Hepatol 16(3):145\u2013159","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2991_CR14","doi-asserted-by":"crossref","unstructured":"Aki D, Hayakawa T, Srirat T et al (2024) The Nr4a family regulates intrahepatic Treg proliferation and liver fibrosis in MASLD models [J]. J Clin Investig, 134(23):e175305","DOI":"10.1172\/JCI175305"},{"issue":"9","key":"2991_CR15","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/s41590-025-02255-y","volume":"26","author":"OP Martin","year":"2025","unstructured":"Martin OP, Wallace MS, Oetheimer C et al (2025) Single-cell atlas of human liver and blood immune cells across fatty liver disease stages reveals distinct signatures linked to liver dysfunction and fibrogenesis [J]. Nat Immunol 26(9):1596\u20131611","journal-title":"Nat Immunol"},{"issue":"8","key":"2991_CR16","doi-asserted-by":"publisher","first-page":"101421","DOI":"10.1016\/j.jhepr.2025.101421","volume":"7","author":"RF Schwabe","year":"2025","unstructured":"Schwabe RF, Tacke F, Sugimoto A et al (2025) Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease [J]. JHEP Rep 7(8):101421","journal-title":"JHEP Rep"},{"issue":"5","key":"2991_CR17","doi-asserted-by":"publisher","first-page":"loae029","DOI":"10.1093\/lifemeta\/loae029","volume":"3","author":"Z Xie","year":"2024","unstructured":"Xie Z, Li Y, Cheng L et al (2024) Potential therapeutic strategies for MASH: from preclinical to clinical development [J]. Life Metabolism 3(5):loae029","journal-title":"Life Metabolism"},{"issue":"17","key":"2991_CR18","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque SM, Bedossa P, Ratziu V et al (2021) A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH [J]. N Engl J Med 385(17):1547\u20131558","journal-title":"N Engl J Med"},{"issue":"10215","key":"2991_CR19","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R et al (2019) Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial [J]. Lancet 394(10215):2184\u20132196","journal-title":"Lancet"},{"issue":"6","key":"2991_CR20","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD et al (2024) A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis [J]. N Engl J Med 390(6):497\u2013509","journal-title":"N Engl J Med"},{"issue":"1","key":"2991_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3350\/cmh.2024.0631","volume":"31","author":"P Danpanichkul","year":"2024","unstructured":"Danpanichkul P, Suparan K, Prasitsumrit V et al (2024) Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations [J]. Clin Mol Hepatol 31(1):74\u201389","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"2991_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jama.2025.19615","volume":"335","author":"H Tilg","year":"2026","unstructured":"Tilg H, Petta S, Stefan N et al (2026) Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review [J]. JAMA 335(2):163\u2013174","journal-title":"JAMA"},{"issue":"2","key":"2991_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41587-019-0329-2","volume":"38","author":"M Mackay","year":"2020","unstructured":"Mackay M, Afshinnekoo E, Rub J et al (2020) The therapeutic landscape for cells engineered with chimeric antigen receptors [J]. Nat Biotechnol 38(2):233\u2013244","journal-title":"Nat Biotechnol"},{"issue":"8","key":"2991_CR24","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/j.cgh.2023.03.041","volume":"21","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Loomba R, Dubourg J et al (2023) Clinical Trial Landscape in NASH [J]. Clin Gastroenterol Hepatol 21(8):2001\u20132014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2991_CR25","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s12072-025-10799-2","volume":"19","author":"W Zhu","year":"2025","unstructured":"Zhu W, Fan C, Zhao Y et al (2025) Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets [J]. Hep Intl 19(4):888\u2013902","journal-title":"Hep Intl"},{"issue":"6","key":"2991_CR26","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ, Resmetirom (2024) First Approval [J]. Drugs 84(6):729\u2013735","journal-title":"Drugs"},{"issue":"2","key":"2991_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jhep.2024.10.018","volume":"82","author":"V Ratziu","year":"2025","unstructured":"Ratziu V, Scanlan TS, Bruinstroop E (2025) Thyroid hormone receptor-\u03b2 analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) [J]. J Hepatol 82(2):375\u2013387","journal-title":"J Hepatol"},{"key":"2991_CR28","doi-asserted-by":"crossref","unstructured":"Song L, Hou Y, Xu D et al (2025) Hepatic FXR-FGF4 is required for bile acid homeostasis via an FGFR4-LRH-1 signal node under cholestatic stress [J]. Cell Metab 37(1):104\u2009\u2013120.e9","DOI":"10.1016\/j.cmet.2024.09.008"},{"key":"2991_CR29","doi-asserted-by":"crossref","unstructured":"Long T, Liu Y, Qin Y et al (2021) Structures of dimeric human NPC1L1 provide insight into mechanisms for cholesterol absorption [J]. Sci Adv 7(34):eabh3997","DOI":"10.1126\/sciadv.abh3997"},{"issue":"3","key":"2991_CR30","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.09.013","volume":"84","author":"E Vilar-Gomez","year":"2025","unstructured":"Vilar-Gomez E, Yates KP, Kleiner DE et al (2025) Genetic and non-genetic drivers of histological progression and regression in MASLD [J]. J Hepatol 84(3):502\u2013516","journal-title":"J Hepatol"},{"issue":"5","key":"2991_CR31","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/HEP.0000000000000786","volume":"82","author":"X Wang","year":"2024","unstructured":"Wang X, Zhang L, Dong B (2024) Molecular mechanisms in MASLD\/MASH-related HCC [J]. Hepatology (Baltimore MD) 82(5):1303\u20131324","journal-title":"Hepatology (Baltimore MD)"},{"issue":"1","key":"2991_CR32","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1038\/s41467-020-17881-3","volume":"11","author":"A Castoldi","year":"2020","unstructured":"Castoldi A, Monteiro LB, van Teijlingen Bakker N et al (2020) Triacylglycerol synthesis enhances macrophage inflammatory function [J]. Nat Commun 11(1):4107","journal-title":"Nat Commun"},{"issue":"1","key":"2991_CR33","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1038\/s41467-020-19263-1","volume":"11","author":"J Kim","year":"2020","unstructured":"Kim J, Kang J, Kang Y-L et al (2020) Ketohexokinase-A acts as a nuclear protein kinase that mediates fructose-induced metastasis in breast cancer [J]. Nat Commun 11(1):5436","journal-title":"Nat Commun"},{"issue":"12","key":"2991_CR34","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/s41418-024-01393-4","volume":"31","author":"Q Zhao","year":"2024","unstructured":"Zhao Q, Han B, Wang L et al (2024) AKR1B1-dependent fructose metabolism enhances malignancy of cancer cells [J]. Cell Death Differ 31(12):1611\u20131624","journal-title":"Cell Death Differ"},{"issue":"5","key":"2991_CR35","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/ncb3338","volume":"18","author":"X Li","year":"2016","unstructured":"Li X, Qian X, Peng L-X et al (2016) A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation [J]. Nat Cell Biol 18(5):561\u2013571","journal-title":"Nat Cell Biol"},{"key":"2991_CR36","doi-asserted-by":"crossref","unstructured":"Butcher DR, Parris CN, Crichton SJ et al (2025) Unlocking the potential of targeting the angiotensin II type 1 receptor in cancer [J]. Oncogene 45(4):479\u2013490","DOI":"10.1038\/s41388-025-03666-9"},{"issue":"5","key":"2991_CR37","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/hep.20665","volume":"41","author":"R Bataller","year":"2005","unstructured":"Bataller R, G\u00e4bele E, Parsons CJ et al (2005) Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats [J]. Hepatology (Baltimore MD) 41(5):1046\u20131055","journal-title":"Hepatology (Baltimore MD)"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02991-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02991-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02991-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:01:23Z","timestamp":1793397683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02991-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["2991"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-02991-4","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}